Preoperative Oral Supplementation With Branched-Chain Amino Acids (BCAA) Improves Postoperative Quality of Life (KMS)
Hepatocellular Carcinoma, Chronic Liver Disease

About this trial
This is an interventional supportive care trial for Hepatocellular Carcinoma focused on measuring QOL, liver
Eligibility Criteria
Inclusion Criteria:
- Patients who underwent elective liver resection for the treatment of hepatocellular carcinoma or adenocarcinoma with chronic liver diseases.
Exclusion Criteria:
- Body weight loss greater than 10 per cent during the 6 months prior to surgery,
- The presence of distant metastases, or seriously impaired function of vital organs due to respiratory, renal or heart disease.
Sites / Locations
- Kochi Medical School
- Kochi Medical School, Kochi University
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Aminolaban EN
Control
Aminoleban EN™ was administered at a dose of 100 g per day commencing two weeks prior to surgery. A 100 g dose of Aminoleban EN™ contains 13.0 g of free amino acids, 13.0 g of gelatin hydrolysate, 1.0 g of casein, 62.1 g of carbohydrate, 7.0 g of lipid, glycyrrhizin, and other components, producing 420 kcal. The AEN group included 40 patients who were administered 100 g of Aminoleban EN™ as 50 g during the day and 50 g as a late evening snack.
The patients were divided into two groups including one group administered Aminoleban (the AEN group) and a control group given no additional dietary supplementation. The total caloric energy intake per day during the study period was assumed to be equal to Aminolaban EN group.